Scarica l'app Stockscreener
6.77
6.11%
0.39
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RLAY Giù?
Forum
Previsione
Precedente Chiudi:
$6.38
Aprire:
$6.37
Volume 24 ore:
2.37M
Relative Volume:
1.30
Capitalizzazione di mercato:
$1.17B
Reddito:
$25.55M
Utile/perdita netta:
$-341.97M
Rapporto P/E:
-2.4179
EPS:
-2.8
Flusso di cassa netto:
$-304.44M
1 W Prestazione:
+7.63%
1M Prestazione:
-3.84%
6M Prestazione:
+136.71%
1 anno Prestazione:
+45.91%
Intervallo 1D:
$6.28
$6.86
Intervallo di 1 settimana:
$6.17
$6.86
Portata 52W:
$1.775
$7.64
Relay Therapeutics Inc Stock (RLAY) Company Profile
Nome
Relay Therapeutics Inc
Settore
Industria
Telefono
617-370-8837
Indirizzo
60 HAMPSHIRE STREET, CAMBRIDGE
Confronta RLAY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
6.77 | 1.11B | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-04-17 | Iniziato | Wells Fargo | Equal Weight |
| 2024-09-10 | Ripresa | Goldman | Buy |
| 2024-09-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-09-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-05-10 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-04-20 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-04-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | Iniziato | Raymond James | Outperform |
| 2023-02-03 | Iniziato | Oppenheimer | Outperform |
| 2022-09-30 | Iniziato | Barclays | Equal Weight |
| 2022-09-02 | Iniziato | Stifel | Buy |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-02-01 | Iniziato | Berenberg | Buy |
| 2021-07-21 | Iniziato | BofA Securities | Buy |
| 2020-12-15 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-11-05 | Iniziato | H.C. Wainwright | Buy |
| 2020-08-10 | Iniziato | Cowen | Outperform |
| 2020-08-10 | Iniziato | Goldman | Buy |
| 2020-08-10 | Iniziato | Guggenheim | Buy |
| 2020-08-10 | Iniziato | JP Morgan | Neutral |
Mostra tutto
Relay Therapeutics Inc Borsa (RLAY) Ultime notizie
Should I hold or sell Relay Therapeutics Inc. stock in 2025CEO Change & AI Based Buy and Sell Signals - newser.com
Key metrics from Relay Therapeutics Inc.’s quarterly data2025 Dividend Review & Technical Entry and Exit Alerts - newser.com
Is Relay Therapeutics Inc. stock a top momentum playJuly 2025 Drop Watch & Daily Market Momentum Tracking - newser.com
Relay Therapeutics Inc.’s volatility index tracking explainedJuly 2025 Price Swings & Capital Protection Trading Alerts - newser.com
Relay Therapeutics Inc. (RLAY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Top 3 Biotech Stocks Capitalizing on the AI Revolution - Investing.com
Top 3 Biotech Stocks Capitalizing on the AI Revolution - Investing.com
Commit To Buy Relay Therapeutics At $5, Earn 22.4% Annualized Using Options - Nasdaq
Citizens reiterates Market Outperform rating on Relay Therapeutics stock By Investing.com - Investing.com Canada
What analysts say about Relay Therapeutics Inc stockChart Pattern Recognition & Outstanding Growth Strategies - earlytimes.in
How Relay Therapeutics Inc. stock compares to growth peersTrade Performance Summary & AI Optimized Trade Strategies - newser.com
Is Relay Therapeutics Inc. stock positioned for long term growth - newser.com
Does Relay Therapeutics Inc. show high probability of reboundProduct Launch & Reliable Price Action Trade Plans - newser.com
Backtesting results for Relay Therapeutics Inc. trading strategiesShare Buyback & Growth Focused Stock Reports - newser.com
Analyzing recovery setups for Relay Therapeutics Inc. investorsEarnings Performance Report & Risk Managed Investment Entry Signals - newser.com
Relay Therapeutics Q3 2025 Earnings Preview - MSN
Why Relay Therapeutics Inc. stock is trending among retail traders2025 Trading Recap & Free Community Supported Trade Ideas - Fundação Cultural do Pará
What machine learning models say about Relay Therapeutics Inc.2025 Investor Takeaways & Daily Entry Point Trade Alerts - newser.com
Why retail investors favor Relay Therapeutics Inc. stockQuarterly Market Summary & AI Enhanced Execution Alerts - newser.com
How to use a screener to detect Relay Therapeutics Inc. breakoutsShare Buyback & Safe Swing Trade Setups - newser.com
Will Relay Therapeutics (RLAY) Board Additions Signal a Shift in Commercialization Strategy? - Yahoo Finance
Relay Therapeutics Inc Stock Analysis and ForecastTrend Following Strategies & Minimal Capital Growth Plans - earlytimes.in
Regression analysis insights on Relay Therapeutics Inc. performanceDollar Strength & AI Powered Market Entry Ideas - newser.com
Using Ichimoku Cloud for Relay Therapeutics Inc. technicalsJuly 2025 PostEarnings & Safe Entry Trade Reports - newser.com
Why hedge funds are buying Relay Therapeutics Inc. stockMarket Volume Summary & Consistent Return Investment Signals - newser.com
Has Relay Therapeutics Inc. found a price floor2025 Trading Recap & Stock Portfolio Risk Control - newser.com
Relay Therapeutics Trims Costs And Stays Well-Funded - Finimize
Full technical analysis of Relay Therapeutics Inc. stockMarket Rally & Safe Entry Trade Reports - newser.com
Wells Fargo Maintains Relay Therapeutics (RLAY) Equal-Weight Recommendation - Nasdaq
Relay Therapeutics (RLAY) Analyst Rating Update by Wells Fargo | RLAY Stock News - GuruFocus
Relay Therapeutics Reports Q3 2025 Financial Progress - TipRanks
Decoding Relay Therapeutics Inc (RLAY): A Strategic SWOT Insight - GuruFocus
Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025 - Investing News Network
Relay Therapeutics (RLAY) Advances Clinical Trials in Breast Can - GuruFocus
Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates - Investing News Network
Relay Therapeutics Inc Reports Q3 2025 EPS of -$0.43, Revenue at $0, Missing Estimates - GuruFocus
Relay Therapeutics slightly misses Q3 net loss estimates, expects cash reserves to fund operations into 2029 - TradingView
Relay Therapeutics Appoints Two New Board Members - TradingView
[10-Q] Relay Therapeutics, Inc. Quarterly Earnings Report | RLAY SEC FilingForm 10-Q - Stock Titan
[8-K] Relay Therapeutics, Inc. Reports Material Event | RLAY SEC FilingForm 8-K - Stock Titan
RLAY: Clinical progress, reduced losses, and strong cash position support operations into 2029 - TradingView
Relay Therapeutics Inc Azioni (RLAY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):